



**Proteomics International**

LABORATORIES LTD

**ASX Release**

**28 July 2021**

**ASX code: PIQ**

## **Update on PromarkerD manufacturing and clarification of engagement with Abcam**

- **Global life science company Abcam plc engaged to produce specialist reagents for the immunoassay version of the PromarkerD test for diabetic kidney disease**
- **Following successful feasibility work Abcam to become non-exclusive supplier of specialist reagents for the PromarkerD test subject to finalisation of terms of a master agreement**
- **Proteomics International in negotiations with a certified manufacturer for the production of the PromarkerD test immunoassay kit in the Northern Hemisphere**
- **Global commercialisation strategy for PromarkerD test on track, with steps including accreditation and regulatory approvals, manufacture and kit assembly and distribution**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) provides an update on manufacture of the immunoassay version of the PromarkerD test and clarification of its engagement with Abcam plc (Abcam) to manufacture PromarkerD reagents [ASX: 22 July 2021]. PromarkerD is a predictive blood test used for the early detection of chronic kidney disease in patients with type-2 diabetes.

In July 2021, Abcam and Proteomics International completed production of specialist protein standards and stabilised recombinant (synthetic) versions of the relevant antibodies required for the PromarkerD test. Having completed the manufacture and feasibility production work successfully and to an appropriate standard, the parties agreed that Abcam would be the non-exclusive supplier of specialist reagents for the PromarkerD test, with the production and supply engagement to be formalised. Orders for reagents from Abcam will be placed on an ad-hoc basis dependent on production requirements. The parties are currently negotiating the formal terms of a master agreement, which will be announced to the market when the agreement is executed.

Production of the PromarkerD immunoassay requires specialist reagents, including synthetic protein standards and antibodies, used to detect the target protein biomarkers in the blood associated with diabetic kidney disease. In order to meet Proteomics International's anticipated worldwide demand for PromarkerD, the Company engaged Abcam, a global life science company and leader in the supply of life science research tools and reagents, with the objective of scaling-up and streamlining the future production of the assay reagents for the European and US markets.

The development work to produce recombinant versions of the antibodies is expected to result in a product that is more consistent and reliable, and suitable for larger scale production without impacting current regulatory approvals for the PromarkerD test.

Manufacture of the PromarkerD immunoassay kits currently occurs under licence in Australia by TGR Biosciences, a wholly owned subsidiary of Abcam plc [ASX: 17 September 2019]. To extend its manufacturing capacity Proteomics International is also in final negotiations for the engagement of a third party to manufacture the immunoassay kit for the PromarkerD test for sale in the Northern Hemisphere, using the specialist reagents.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

The Company will continue to provide updates to the market on key milestones for the global commercialisation strategy for the PromarkerD test, including the terms of any material agreements with new partners as and when they are signed.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

**About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

PromarkerD is a predictive test for the early detection of chronic kidney disease (CKD) in patients with type-2 diabetes. CKD is one of the major complications arising from diabetes and if unchecked can lead to dialysis or kidney transplant.

The patented PromarkerD test system uses a simple blood test to detect a unique ‘fingerprint’ of the early onset of disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)).

In clinical studies published in leading journals PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. The PromarkerD immunoassay, the PromarkerD mass spectrometry assay, and the PromarkerD software hub have each achieved CE Mark registration in the European Union.

Further information is available through the PromarkerD web portal.

*To visit the PromarkerD virtual booth please see: [www.PromarkerD.com/product](http://www.PromarkerD.com/product)*

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth’s QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the Company's world-leading test for diabetic kidney disease, PromarkerD. The Company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Corporate Advisor & Investor Relations  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@euroz.com](mailto:kmoss@euroz.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)